1. Home
  2. CNS vs WGS Comparison

CNS vs WGS Comparison

Compare CNS & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$63.27

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$70.64

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNS
WGS
Founded
1986
2017
Country
United States
United States
Employees
N/A
1300
Industry
Investment Managers
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
CNS
WGS
Price
$63.27
$70.64
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$72.50
$140.71
AVG Volume (30 Days)
242.1K
714.0K
Earning Date
04-15-2026
04-29-2026
Dividend Yield
4.24%
N/A
EPS Growth
N/A
N/A
EPS
2.97
N/A
Revenue
$427,536,000.00
N/A
Revenue This Year
$7.83
$29.98
Revenue Next Year
$11.02
$24.85
P/E Ratio
$21.35
$1,251.58
Revenue Growth
4.07
N/A
52 Week Low
$58.39
$55.17
52 Week High
$82.24
$170.87

Technical Indicators

Market Signals
Indicator
CNS
WGS
Relative Strength Index (RSI) 42.62 34.67
Support Level $59.65 $68.55
Resistance Level $64.43 $76.21
Average True Range (ATR) 2.04 5.43
MACD -0.30 -0.20
Stochastic Oscillator 30.73 7.04

Price Performance

Historical Comparison
CNS
WGS

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: